Title of article :
Application of a colorimetric chain-termination assay for characterization of reverse transcriptase from 3-azido-2,3-deoxythymidineresistant HIV isolates
Author/Authors :
Shao، Xing-Wu نويسنده , , Hjalmarsson، Sandra نويسنده , , Lennerstrand، Johan نويسنده , , Svennerholm، Bo نويسنده , , Blomberg، Jonas نويسنده , , Kallander، Clas F. R. نويسنده , , Gronowitz، J. Simon نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2002
Abstract :
Two different enzyme assays, both based on the interaction of native reverse transcriptase (RT) and 3ʹ-azido-2ʹ,3ʹ-deoxythymidine triphosphate (AZT-TP), were used to characterize the enzymes from 18 HIV-1 isolates with decreased sensitivity to AZT in cell culture. The first assay, which measures the balance between incorporation and excision of AZT monophosphate in the presence of dNTP substrate (in terms of IC50), gave an approx. 9-fold variation in sensitivity to AZT-TP. There was a correlation between the IC50 values and the sensitivity of the corresponding virus to AZT in cell culture (r = 0.60, P < 0.01). The second assay, which was designed specifically for measurement of chain termination in the absence of dNTP substrate (as the concentration of AZT-TP giving 50% residual primer function, or CT50), revealed a more than 600-fold difference between the different isolate RTs. For the majority of enzymes there was a strict correlation between the results from the two assays; however, four isolates exhibited significantly higher CT50/IC50 ratios than the other isolates. These differences were not related to sensitivity of the corresponding viruses to AZT but to the occurrence of certain mutations in their pol gene. The four deviating isolates contained either a minimum of four AZT-specific substitutions, including Thr-215 (right arrow) Tyr (isolates 134 and 143), or some of the known specific substitutions combined with Thr-39 (right arrow) Ala (isolates 80 and 157). The Thr-39 (right arrow) Ala substitution has previously been recorded in connection with AZT/Foscarnet combination therapy.
Journal title :
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
Journal title :
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY